4-(1-(4-溴苯基)乙基)吗啉 | 933785-12-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(1-(4-溴苯基)乙基)吗啉
• 英文名称: 4-(1-(4-bromophenyl)ethyl)morpholine
• 英文别名: 4-[1-(4-bromophenyl)ethyl]morpholine
• CAS: 933785-12-7
• 化学式: C₁₂H₁₆BrNO
• 分子量: 270.169
• InChiKey: NCRGTUOKKUWAEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(1-(4-溴苯基)乙基)吗啉 在 [(2-di-cyclohexylphosphino-3,6-dimethoxy-2’,4’,6’-triisopropyl-1,1‘-biphenyl)-2-(2‘-amino-1,1’-biphenyl)]palladium(II) methanesulfonate 、 氨 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 为溶剂， 反应 36.0h， 生成 5-(methylamino)-6-(3-methylimidazo[4,5-c]pyridin-7-yl)-3-[4-[(1S)-1-morpholinoethyl]anilino]pyrazine-2-carboxamide formate salt
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER
  [FR] PYRAZINE-2-CARBOXAMIDES SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE HPK1 POUR LE TRAITEMENT DU CANCER

  摘要：

  There are disclosed certain substituted pyrazine-2-carboxamides of Formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are inhibitors of hematopoietic progenitor kinase 1 (HPK1) and are thereby particularly useful in the treatment or prophylaxis of cancer.

  公开号：

  WO2023001794A1
• 作为产物：
  描述：

  对溴乙基苯 在 四溴化碳 、 (4,4'-di-tert-butyl-2,2'-dipyridyl)-bis-(2-phenylpyridine(-1H))-iridium(III) hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 生成 4-(1-(4-溴苯基)乙基)吗啉
  参考文献：
  名称：

  Visible-light-mediated benzylic sp3 C–H bond functionalization to C–Br or C–N bond

  摘要：

  A visible-light-promoted functionalization of unactivated benzylic sp(3) C-H bonds was developed. Ethylbenzene derivatives were converted to the corresponding benzyl bromides or afforded benzylamine derivatives in a one-pot manner under visible light photoredox conditions. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2016.04.036

文献信息

• [EN] PLK-4 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME<br/>[FR] INHIBITEURS DE PLK4 ET MÉTHODE DE TRAITEMENT DU CANCER À L'AIDE DE CEUX-CI
  申请人：UNIV HEALTH NETWORK

  公开号：WO2012048411A1

  公开（公告）日：2012-04-19

  The invention is directed to a compound represented by the following Structural Formula (I) and (II) and pharmaceutically acceptable salts thereof: (Formula (I)); (Formula (IV)). Compounds represented by this structural formula are kinase inhibitors and are, therefore, disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

  这项发明涉及一种由以下结构式（I）和（II）表示的化合物及其药学上可接受的盐：（结构式（I））；（结构式（IV））。由该结构式表示的化合物是激酶抑制剂，因此在此披露用于癌症治疗。结构式中变量的定义在此提供。
• [EN] NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES<br/>[FR] NOUVEAUX COMPOSÉS UTILES POUR LE TRAITEMENT DE MALADIES DÉGÉNÉRATIVES ET INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2010010189A1

  公开（公告）日：2010-01-28

  Novel [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a Formula represented by the Formula (I). These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotox in states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g. diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection) and proliferative diseases.

  揭示了具有由公式（I）表示的公式的新型[1,2,4]三唑并[1,5-a]吡啶化合物。这些化合物可以制备为药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，例如涉及软骨降解、骨骼和/或关节降解的疾病，例如骨关节炎；以及涉及炎症或免疫反应的疾病，如克罗恩病、类风湿性关节炎、牛皮癣、过敏性气道疾病（例如哮喘、鼻炎）、儿童特发性关节炎、结肠炎、炎性肠病、内毒素驱动的疾病状态（例如旁路手术后的并发症或慢性内毒素状态导致的慢性心力衰竭等），涉及软骨周转障碍的疾病（例如涉及软骨细胞合成刺激的疾病）、先天性软骨畸形、与IL6过度分泌和移植排斥（例如器官移植排斥）以及增生性疾病相关的疾病。
• [EN] [1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS<br/>[FR] [1, 2, 4]TRIAZOLO[1, 5-A]PYRIDINES UTILISÉES COMME INHIBITEURS DE JAK
  申请人：GALAPAGOS NV

  公开号：WO2010010184A1

  公开（公告）日：2010-01-28

  Novel [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a Formula represented by the following: (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, joint disease, inflammation, and others.

  揭示了一种具有以下式表示的化学式的新型[1,2,4]三唑并[1,5-a]吡啶化合物（I）。这些化合物可以制备为药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，例如关节疾病、炎症等。
• Achieving Aliphatic Amine Addition to Arylalkynes via the Lewis Acid Assisted Triazole-Gold (TA-Au) Catalyst System
  作者：Teng Jia、Shengyu Fan、Fengmian Li、Xiaohan Ye、Wenke Zhang、Zhiguang Song、Xiaodong Shi

  DOI：10.1021/acs.orglett.1c02098

  日期：2021.8.6

  Transition metal catalyzed intermolecular hydroamination of the arylalkynes with aliphatic amine is generally problematic due to the good coordination between amine and metal cation. With the combination of 1,2,3-triazole coordinated gold(I) catalyst (TA-Au) and Zn(OTf)2 cocatalyst, this challenging transformation was achieved with good to excellent yields and regioselectivity. Compared to previously

  由于胺和金属阳离子之间的良好配位，过渡金属催化的芳基炔与脂肪胺的分子间加氢胺化通常存在问题。通过结合 1,2,3-三唑配位金 (I) 催化剂 (TA-Au) 和 Zn(OTf) 2助催化剂，实现了这一具有挑战性的转化，并具有良好至优异的产率和区域选择性。与之前报道的方法相比，该方法提供了一种替代催化剂系统，以高效率和实用条件实现这一基本化学转化。
• HETEROCYCLIC COMPOUNDS
  申请人：GAUL Christoph

  公开号：US20090203688A1

  公开（公告）日：2009-08-13

  The invention relates to compounds of formula I and salts thereof wherein the substituents are as defined in the specification, processes for the preparation thereof; to pharmaceuticals containing such compounds, in particular for the use in one or more Protein tyrosine kinase mediated diseases.

  该发明涉及公式I的化合物及其盐，其中取代基如规范中定义，以及其制备方法；含有这种化合物的药物，特别用于在一个或多个蛋白酪氨酸激酶介导的疾病中使用。